S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
Critical asset just had biggest fall on record (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Price, News & Analysis

$32.66
+0.54 (+1.68%)
(As of 03/1/2024 ET)
Today's Range
$32.31
$34.01
50-Day Range
$23.82
$32.80
52-Week Range
$22.67
$47.48
Volume
1.95 million shs
Average Volume
1.86 million shs
Market Capitalization
$3.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.93

Intellia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
104.9% Upside
$66.93 Price Target
Short Interest
Bearish
12.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.56mentions of Intellia Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$962,177 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.57) to ($5.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

181st out of 950 stocks

Diagnostic Substances Industry

4th out of 9 stocks


NTLA stock logo

About Intellia Therapeutics Stock (NASDAQ:NTLA)

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Stock Price History

NTLA Stock News Headlines

Is CRISPR Therapeutics the NVIDIA of gene editing? (NTLA)
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Analysts see over 50% gains in these 2 mid-cap biotech stocks (NTLA)
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Intellia Therapeutics Is On The Move
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 5.8%
Intellia Therapeutics just downgraded at Goldman Sachs, here's why
Q4 2023 Intellia Therapeutics Inc Earnings Call
A Preview Of Intellia Therapeutics's Earnings
See More Headlines
Receive NTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/03/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
598
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$66.93
High Stock Price Target
$107.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+104.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$-481,190,000.00
Net Margins
-893.34%
Pretax Margin
-1,326.51%

Debt

Sales & Book Value

Annual Sales
$36.28 million
Book Value
$10.93 per share

Miscellaneous

Free Float
93,223,000
Market Cap
$3.14 billion
Optionable
Optionable
Beta
1.80
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. John M. Leonard M.D. (Age 67)
    President, CEO & Director
    Comp: $1.06M
  • Mr. Glenn G. Goddard CPAMr. Glenn G. Goddard CPA (Age 53)
    Executive VP, CFO & Treasurer
    Comp: $630.91k
  • Dr. Laura Sepp-Lorenzino Ph.D. (Age 63)
    Executive VP & Chief Scientific Officer
    Comp: $670.58k
  • Mr. James E. Basta Esq. (Age 58)
    J.D., Executive VP, General Counsel & Corporate Secretary
    Comp: $616.15k
  • Dr. David Lebwohl M.D. (Age 69)
    Executive VP & Chief Medical Officer
    Comp: $671.42k
  • Mr. Derek Hicks (Age 51)
    Executive VP & Chief Business Officer
    Comp: $823.42k
  • Mr. Nessan Bermingham Ph.D. (Age 51)
    Founder & Member of Scientific Advisor Board
    Comp: $1.38M
  • Dr. Rachel E. Haurwitz Ph.D. (Age 38)
    Co-Founder
  • Dr. Andrew May Ph.D.
    Founder and Member of Scientific Advisor Board
  • Dr. Jennifer A. Doudna Ph.D. (Age 59)
    Founder & Member of Scientific Advisor Board














NTLA Stock Analysis - Frequently Asked Questions

Should I buy or sell Intellia Therapeutics stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTLA shares.
View NTLA analyst ratings
or view top-rated stocks.

What is Intellia Therapeutics' stock price target for 2024?

16 Wall Street analysts have issued 1-year target prices for Intellia Therapeutics' stock. Their NTLA share price targets range from $29.00 to $107.00. On average, they predict the company's share price to reach $66.93 in the next year. This suggests a possible upside of 104.9% from the stock's current price.
View analysts price targets for NTLA
or view top-rated stocks among Wall Street analysts.

How have NTLA shares performed in 2024?

Intellia Therapeutics' stock was trading at $30.49 at the start of the year. Since then, NTLA stock has increased by 7.1% and is now trading at $32.66.
View the best growth stocks for 2024 here
.

When is Intellia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NTLA earnings forecast
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings data on Thursday, February, 22nd. The company reported ($1.46) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.01. The business had revenue of ($1.92) million for the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative trailing twelve-month return on equity of 43.91%. During the same period in the prior year, the business posted ($1.40) earnings per share.

What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (12.74%), Vanguard Group Inc. (9.32%), Sumitomo Mitsui Trust Holdings Inc. (3.88%), Nikko Asset Management Americas Inc. (3.88%), Federated Hermes Inc. (2.25%) and Price T Rowe Associates Inc. MD (2.05%). Insiders that own company stock include Caroline Dorsa, David Lebwohl, Eliana Clark, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Laura Sepp-Lorenzino and Muna Bhanji.
View institutional ownership trends
.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTLA) was last updated on 3/3/2024 by MarketBeat.com Staff